Version of Record online: 28 NOV 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 44, Issue 6, pages 1400–1403, December 2006
How to Cite
Muir, A. J. and McHutchison, J. G. (2006), Growth factors during HCV therapy may be “cost-effective”, but are they “effective”?. Hepatology, 44: 1400–1403. doi: 10.1002/hep.21426
See Article on Page 1598.
Potential conflict of interest: Dr. McHutchison and Dr. Muir are consultants for, are on the speakers' bureau of, and received grants from Schering Plough. They received grants from Roche, GlaxoSmithKline, and Pfizer.
- Issue online: 28 NOV 2006
- Version of Record online: 28 NOV 2006
- 3A descriptive assessment of the current treatment patterns for hepatitis C in a health benefits company population. Gastroenterology 2005; 128( Suppl 2): A724–A725., , .
- 8Treatment of chronic hepatitis C virus genotype 1 with peginterferon alfa-2b, high weight based dose ribavirin and epoetin alfa enhances sustained virologic response [Abstract]. HEPATOLOGY 2005; 42( Suppl 1): 217A., , , , , , et al.
- 10Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100: 1415–1419., , , , , , et al.Direct Link:
- 18A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004; 99: 2359–2364., , .Direct Link:
- 19Efficacy and safety of eltrombopag, an oral platelet growth factor, in sujects with HCV associated thrombocytopenia: preliminary results from a phase II multicenter, randomised, placebo controlled, double-blind, dose-ranging study. Gastroenterology 2006; 130( Suppl 2): A–762., , , et al.